EMV Capital PLC · LSE:EMVC
EMV Capital — ProAxsis — 2nd Annual Capital Markets Day (March 2017)
23 slides from EMV Capital's conference presentation, March 2017

Slide 1: New standard of care for respiratory disease
2nd Annual Capital Markets Day Professor Brian Walker Co-Founder & CSO, ProAxsis Ltd New standard of care for respiratory disease

Slide 2: Prof. Brian Walker
Detect, capture and measure proteases Prof. Brian Walker Chief Scientific Officer Brian.Walker@proaxsis.com www.proaxsis.com @ProAxsis

Slide 3: Proteases are involved in multiple diseases
Proteases are involved in multiple diseases AIDS SalesDiabetes (HIV Protease) (DPP IV) Alzheimer’s (β and γ-secretase) Angiodema (Kallikrein) Pulmonary embolism Hypertension (Thrombin, Factor Xa) (ACE/NEP/ECE) Arthritis/Inflammation Heart attack (TACE, MMPs) (Thrombin, Factor Xa) Chronic wounds Prot

Slide 4: ProteaseTags offer a novel solution
ProteaseTags® offer a novel solution Small chemical probes that act as irreversible inhibitors targeting the active site of specific proteases Allows the capture of active proteases in multiple biological samples 3

Slide 5: Incorporating ProteaseTags in to an Activity Based Immunoassay
Incorporating ProteaseTags® in to an Activity Based Immunoassay Sample containing Biotin- Multiple proteases ProteaseTag Target protease captured Streptavidin Coated well ProteaseTag binds to streptavidin Antibody-HRP HRP Substrate Antibody binds to captured protease

Slide 6: New standard of care for respiratory disease
2nd Annual Capital Markets Day Dr David Ribeiro CEO, ProAxsis Ltd New standard of care for respiratory disease

Slide 7: Dr. David Ribeiro, PhD
Detect, capture and measure proteases Dr. David Ribeiro, PhD Chief Executive Officer David.Ribeiro@proaxsis.com www.proaxsis.com @ProAxsis

Slide 8: An experienced leadership team
An experienced leadership team Dr. David Ribeiro – CEO Senior management at Pfizer, Solvay Healthcare and Encysive Pharma. Most recently, at Pharmaxis, worked on a diagnostic test for assessing bronchial hyper-responsiveness in asthma, and a therapeutic product designed for the chronic treatment of

Slide 9: Our Vision for ProAxsis
Our Vision for ProAxsis To become the premier company for the provision of robust, sensitive and highly specific assays for the measurement of active proteases. To translate this technology platform to Point-of-Care devices for protease biomarker diagnostics. 3

Slide 10: Proteases are involved in multiple diseases
Proteases are involved in multiple diseases AIDS SalesDiabetes (HIV Protease) (DPP IV) Alzheimer’s (β and γ-secretase) Angiodema (Kallikrein) Pulmonary embolism Hypertension (Thrombin, Factor Xa) (ACE/NEP/ECE) Arthritis/Inflammation Heart attack (TACE, MMPs) (Thrombin, Factor Xa) Chronic wounds Prot

Slide 11: COPD is an umbrella term used to describe progressive lung diseases
COPD is an umbrella term used to describe progressive lung diseases 16.3m diagnosed in EU, 17.7m US, >75m China UK hospital admission for exacerbation £5000. 9 days in hospital with IV antibiotics. 5

Slide 12: 40,000 EU and 30,000 US Diagnosed
CF is a life-limiting inherited condition caused by a faulty gene 40,000 EU and 30,000 US Causes mucus to gather in the lungs Diagnosed and digestive system and creates a range of challenging symptoms 6

Slide 13: A world-renowned scientific advisory board
A world-renowned scientific advisory board Prof Stuart Elborn (Belfast) – Chairman Dean of the School of Medicine, Dentistry and BioMedical Sciences Former President of European CF Society Prof Marcus Mall (Heidelberg) Prof Patrick Flume (South Carolina) Director of the Dept. of Translational Profes

Slide 14: No suitable biomarker test….until now
No suitable biomarker No suitable test….until biomarker now test available until now C-reactive protein (CRP) levels are sometimes measured in the clinic, but KOLs noted that this is not a reliable predictor of exacerbations as CRP levels are often normal even when the patient is having an exacerb

Slide 15: Elevated NE is predictive of exacerbation
Elevated NE is predictive of exacerbation 400 NE Activity (ng/ml) 300 200 100 0 Stable Exacerbation Sputum NE is the most informative biomarker to monitor disease activity Elevations in sputum NE levels predict time to next exacerbation and future hospital admissions* Moffitt et al, P102, British Th

Slide 16: First Activity based immunoassay kit for measuring NE now launched
First Activity based immunoassay kit for measuring NE now launched Recent kit supplies to UK, Ireland, Germany, Switzerland, Sweden and USA CE Mark expected in H2 2016 Immunoassay accepted for use in a pharma company trial, and being validated by several others Research collaborations with a

Slide 17: First Point of Care test due to launch in 2017
First Point of Care test due to launch in 2017 Launch strategy CE mark Launch first as general IVD for use in clinic – elevate clinician awareness Follow-up launch as point-of-care IVD for use by the patient at home Business model Western/Northern Europe: Direct sales Rest of Europe/Asia/U

Slide 18: Minimal current competition
Minimal current competition Aseptika NEATstik™ Exotoxin A Active NE as marker of lung disease Test + Iron transport molecule as marker of P. activity aeruginosa infection Sample Sputum Sputum Lab-based version? Detects all exacerbations? X limited to those due to PA infection Platform of respi

Slide 19: Timeline for POC market entry
Timeline for POC market entry 2015 2016 2017 H2 H1 H2 H1 Immunoassay launch POC development Validation Transfer to manufacturing Series A close CE marking – general IVD CE marking – self test EU launch – general IVD EU launch – self test 13

Slide 20: Key drivers of the POC market
Key drivers of the POC market Target population is moderate-severe COPD and adult CF patients (48 million) Greater than 85% of KOLs expected moderate-to-high usage of NEATstik POC amongst their colleagues working with CF and COPD patients Launch of NEATstik planned for H1 2017 in Europe and H1

Slide 21: Fundraising up to £7million
Use of proceeds to drive success Fundraising up to £7million Prospective pan-European COPD trial Complete NEATstik POC development programme and CE marking Build commercial team and launch across Europe Ongoing development and launch of further respiratory protease target assays 15

Slide 22: Protease diagnostics company
Protease diagnostics company Developing and commercializing immunoassay kits and rapid, highly sensitive point-of- care (POC) tests for the capture, detection and measurement of active protease biomarkers of disease Launched first immunoassay kit to pharma drug development and academic research

Slide 23: Any Questions?
Any Questions? David.Ribeiro@proaxsis.com www.proaxsis.com @proaxsis
Source: Internet Archive copy of netscientific.net
More decks from EMV Capital PLC
H1 2026 Earnings Presentation27 slides · Sep 24, 2026
FY2025 Earnings Presentation26 slides · May 19, 2026
Investor Presentation (February 2026)29 slides · Feb 26, 2026
Investor Presentation (December 2025)27 slides · Dec 1, 2025
H1 2025 Earnings Presentation31 slides · Sep 30, 2025
FY2024 Earnings Presentation35 slides · June 2025